Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talsaclidine in mild to moderate Alzheimer's dementia
NCT02249351Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 1999
- Primary completion
- May 2000
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of talsaclidine in Alzheimer's disease (AD), sponsored by Boehringer Ingelheim. Started Dec 1999; status: terminated.
02
Drugs
talsaclidine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02249351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249351.